Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
It has been reported that the presence of anti‐nuclear antibody against a 210kDa glycoprotein of nuclear pore complex (anti‐gp210) is highly specific for primary biliary cirrhosis (PBC). The aim of the present study was to investigate the significance of anti‐gp210, especially as a prognostic marker. The presence of anti‐gp210 was ascertained in 113 patients with PBC and 162 controls by indirect immunofluorescence assay using HepG2 cells and immunoblotting analysis using nuclear extracts from HeLa cells. Anti‐gp210 was detected in 25 of the 113 (22.1%) patients. None of the 162 controls was positive for anti‐gp210. The appearance and titre of anti‐gp210 in the patients with PBC did not vary from the time of diagnosis and through their clinical course. Anti‐mitochondrial antibodies (AMA), including antibodies against pyruvate dehydrogenase complex, branched chain α‐ketoacid dehydrogenase complex and α‐ketoglutarate dehydrogenase complex, were not detected by enzyme‐linked immunosorbent assay in five of the 113 (4.4%) patients with PBC. However, anti‐gp210 alone was positive in one of these five patients. The difference in prognosis was statistically significant; patients with PBC positive for anti‐gp210 died from hepatic failure more frequently than those who were negative (P < 0.01), although there were no statistically significant differences in the frequency of jaundice and the histological stage at the time of diagnosis between the two groups. We suggest that the presence of anti‐gp210 is one of the independent prognostic markers able to predict, at the time of diagnosis, a poor outcome in patients with PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gershwin, M. E., Mackay, I. R., Sturgess, A., & Coppel, R. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3525 · Cited by 557
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504
Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis.
Fussey, S. P., Guest, J. R., James, O. F., Bassendine, M. F., & Yeaman, S. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.22.8654 · Cited by 273
Nickowitz, R. E., Wozniak, R. W., Schaffner, F., & Worman, H. J. (1994) · Gastroenterology · doi:10.1016/s0016-5085(94)95333-3 · Cited by 96
Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis
Lozano, F., Parés, A., Borche, L., Plana, M., Gallart, T., Rodés, J., & Vives, J. (1988) · Hepatology · doi:10.1002/hep.1840080438 · Cited by 94
Lassoued, K., Brenard, R., Degos, F., Courvalin, J.-C., Andre, C., Danon, F., Brouet, J.-C., Zine-El-Abidine, Y., Degott, C., Zafrani, S., et al. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91246-3 · Cited by 83
Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis
Ruffatti, A., Arslan, P., Floreani, A., Vestro, G. D. S., Calligaro, A., Naccarato, R., & Todesco, S. (1985) · Journal of Clinical Immunology · doi:10.1007/bf00918255 · Cited by 45
Cited by
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Invernizzi, P., Podda, M., Battezzati, P. M., Crosignani, A., Zuin, M., Hitchman, E., Maggioni, M., Meroni, P. L., Penner, E., & Wesierska-Gadek, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00040-4 · Cited by 455
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis
Muratori, P., Muratori, L., Ferrari, R., Cassani, F., Bianchi, G., Lenzi, M., Rodrigo, L., Linares, A., Fuentes, D., & Bianchi, F. B. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07257.x · Cited by 204
“Recently, the systematic search for anti-gp210 in a large Japanese series showed that anti-gp210 positive PBC patients died from hepatic failure more frequently”
BackgroundCorrelation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., Worman, H. J., Gershwin, E. M., Podda, M., & Invernizzi, P. (2006) · Hepatology · doi:10.1002/hep.21172 · Cited by 177
Metadata
- Authors
- ITOH, S., ICHIDA, T., YOSHIDA, T., HAYAKAWA, A., UCHIDA, M., TASHIRO‐ITOH, T., MATSUDA, Y., ISHIHARA, K., & ASAKURA, H.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 1998-03
- Volume
- 13
- Issue
- 3
- Pages
- 257-265
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W2106004417
- Cited by
- 118
- References
- 7
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. https://app.cochat.ai/papers/10.1111/j.1440-1746.1998.01553.x
- The paper
- ITOH, S., ICHIDA, T., YOSHIDA, T., HAYAKAWA, A., UCHIDA, M., TASHIRO‐ITOH, T., MATSUDA, Y., ISHIHARA, K., & ASAKURA, H. (1998). Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.1998.01553.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.